| Ticker |
APGE
|
| CIK | 0001974640 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM, MA, 02453 |
| Website | apogeetherapeutics.com |
| Phone | 650-394-5230 |
| CEO | Michael Henderson |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established BlockbustersWe just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ:APGE) ranks 6th on this list. Elite money managers are aggressively accumulating Apogee Therapeutics, Inc. (NASDAQ:APGE) stock, viewing it as the primary challenger to established blockbuster drugs in the immunology space. The firm recently released positive Phase […] Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart DataApogee Therapeutics recently completed a follow-on equity offering of approximately US$403,000,000, issuing 5,750,000 common shares at US$70.00 each after reporting positive 52-week Phase 2 APEX data for its lead atopic dermatitis drug candidate, zumilokibart. The Phase 2 results highlighted zumilokibart’s durable responses with less frequent 3- and 6-month maintenance dosing, while the fresh capital bolsters Apogee’s ability to fund later-stage clinical development. Next, we’ll examine how... Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 MillionSAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 750,000 additiona Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for InvestorsThis biotech innovator in immunology reported a notable insider sale as its stock outperformed and drug development efforts continue. Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public OfferingSAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from |
